- Home
- HRTX vs VYGR Comparison
HRTX vs VYGR Comparison
Compare HRTX & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- VYGR
- Stock Information
- Founded
- HRTX 1983
- VYGR 2013
- Country
- HRTX United States
- VYGR United States
- Employees
- HRTX N/A
- VYGR N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- VYGR Health Care
- Exchange
- HRTX Nasdaq
- VYGR Nasdaq
- Market Cap
- HRTX 206.9M
- VYGR 231.9M
- IPO Year
- HRTX 1987
- VYGR 2015
- Fundamental
- Price
- HRTX $1.21
- VYGR $4.26
- Analyst Decision
- HRTX Strong Buy
- VYGR Strong Buy
- Analyst Count
- HRTX 2
- VYGR 8
- Target Price
- HRTX $4.50
- VYGR $16.71
- AVG Volume (30 Days)
- HRTX 1.4M
- VYGR 664.7K
- Earning Date
- HRTX 11-11-2025
- VYGR 11-11-2025
- Dividend Yield
- HRTX N/A
- VYGR N/A
- EPS Growth
- HRTX N/A
- VYGR N/A
- EPS
- HRTX N/A
- VYGR N/A
- Revenue
- HRTX $149,694,000.00
- VYGR $42,580,000.00
- Revenue This Year
- HRTX $10.62
- VYGR N/A
- Revenue Next Year
- HRTX $12.99
- VYGR $107.07
- P/E Ratio
- HRTX N/A
- VYGR N/A
- Revenue Growth
- HRTX 9.78
- VYGR N/A
- 52 Week Low
- HRTX $1.04
- VYGR $2.65
- 52 Week High
- HRTX $2.68
- VYGR $8.28
- Technical
- Relative Strength Index (RSI)
- HRTX 28.21
- VYGR 63.67
- Support Level
- HRTX $1.25
- VYGR $4.04
- Resistance Level
- HRTX $1.27
- VYGR $4.51
- Average True Range (ATR)
- HRTX 0.06
- VYGR 0.30
- MACD
- HRTX 0.01
- VYGR 0.04
- Stochastic Oscillator
- HRTX 8.70
- VYGR 77.62
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.